Combining targeted therapies: practical issues to consider at the bench and bedside.

Area of Science:

• Oncology
• Pharmacology
• Clinical Trial Design

Background:

• Combining targeted therapies in early clinical development presents practical challenges.
• Tumor resistance, redundant signaling pathways, and single-agent therapy failures necessitate combinatorial approaches.

Purpose of the Study:

• To review challenges in combinatorial targeted therapy development.
• To propose novel clinical trial designs for personalized combination treatments.

Main Methods:

• Review of strategies for combinatorial therapy, including multitargeted kinase inhibitors.
• Discussion of considerations such as tumor heterogeneity, pathway targeting, and translation from bench to bedside.
• Exploration of trial design elements like target populations and combination with diagnostics.

Main Results:

• Identified key issues in combining targeted therapies: resistance, pathway redundancy, tumor heterogeneity, and translation challenges.
• Highlighted the need for strategies like hitting multiple targets, inhibiting diverse pathways, and synthetic lethality.
• Emphasized the role of emerging technologies like multiplexed assay platforms and bioinformatics.

Conclusions:

• Effective combinatorial targeted therapy requires careful consideration of numerous practical and scientific issues.
• Novel clinical trial designs are essential for optimizing personalized combination treatments.
• Advancements in technology will significantly influence future combinatorial drug development and clinical trials.